We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Our knowledge, expertise & publications
Deals & Cases
25 July 2022
Mosanna Therapeutics AG, a Basel-based biotechnology company developing the advanced small molecule MOS118 (formerly know as AVE0118) for the treatment of metabolic obstructive sleep apnea, closes a Seed Financing Round led by Forty51 Ventures. The proceeds will be used for formulation and manufacturing optimization of MOS118 and for regulatory activities in preparation of the first Phase 1b clinical trial. VISCHER advises Mosanna Therapeutics AG since its incorporation on all Swiss legal matters. The VISCHER team includes Matthias Staehelin (Partner) and Timothy Woodtli (Associate), both Corporate/M&A.
Categories: Corporate and Commercial, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk
Attorney at Law and Civil Law Notary
Attorney at Law
Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics...
Eurocine Vaccines and Redbiotec have signed a research and partnership agreement for the development...
Engimmune Therapeutics AG, a biotech company based in Basel developing novel T-cell receptor...
Opt-in for our regular updates, news, views, insights and more.